For Q1 FY2026 ended March 31, 2026, Kiniksa reported revenue of $214.3M, up 55.5% year-over-year. Net income was $22.6M, a 164.6% increase, and diluted EPS was $0.27, up 145.5%. Operating income rose 120.5% to $29.3M. The company had $190.0M in cash and $605.7M in equity, with no long-term debt.
•Revenue grew 55.5% YoY to $214.3M.
•Net income surged 164.6% to $22.6M.
•Diluted EPS increased 145.5% to $0.27.
•Cash and equity stood at $190.0M and $605.7M, respectively, with no long-term debt.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company develops and commercializes medical therapies globally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis
KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. Formerly known as Kiniksa Pharmaceuticals, Ltd., the company rebranded as Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
What does Kiniksa Pharmaceuticals International (KNSA) do?
Kiniksa Pharmaceuticals International, plc is a biopharmaceutical company focused on developing and commercializing medical therapies globally. Its primary marketed product is ARCALYST, an interleukin-1alpha and 1beta cytokine trap used to treat recurrent pericarditis, a chronic autoinflammatory cardiovascular disease, and cardiac sarcoidosis. The company also has a pipeline including KPL-387, an investigational fully human immunoglobulin G2 monoclonal antibody currently in Phase 2/3 clinical trials for recurrent pericarditis, and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody in pre-clinical development. Kiniksa operates in the drug manufacturing sector, specifically within the specialty and generic pharmaceuticals industry.
Where is Kiniksa Pharmaceuticals International (KNSA) listed and what currency does it trade in?
Kiniksa Pharmaceuticals International, plc is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol KNSA. Its shares are traded in US Dollars (USD). The company is headquartered in London, United Kingdom, and its stock is accessible to investors through US exchanges, reflecting its primary listing in the United States.
What sector and industry does Kiniksa Pharmaceuticals International (KNSA) belong to?
Kiniksa Pharmaceuticals International, plc operates in the Healthcare sector and is classified under the Drug Manufacturers - Specialty & Generic industry. This means the company is involved in the research, development, and commercialization of pharmaceutical products, with a focus on specialty drugs that target specific medical conditions. Its lead product, ARCALYST, addresses rare inflammatory diseases, aligning with the specialty pharmaceutical segment.
Where is Kiniksa Pharmaceuticals International (KNSA) headquartered and what markets does it serve?
Kiniksa Pharmaceuticals International, plc is headquartered in London, United Kingdom, and serves global markets. The company develops and commercializes therapies for patients worldwide, with a particular emphasis on the United States, where its product ARCALYST is approved for recurrent pericarditis and cardiac sarcoidosis. Its pipeline candidates, such as KPL-387, are also being developed for global use. The company was originally incorporated in 2015 as Kiniksa Pharmaceuticals, Ltd. and rebranded to its current name in June 2024.
What are the main products in Kiniksa Pharmaceuticals International's (KNSA) portfolio?
Kiniksa Pharmaceuticals International, plc's main commercial product is ARCALYST, an interleukin-1alpha and 1beta cytokine trap approved for treating recurrent pericarditis and cardiac sarcoidosis. In its pipeline, the company is developing KPL-387, an investigational fully human immunoglobulin G2 monoclonal antibody currently in Phase 2/3 clinical trials for recurrent pericarditis, and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody in pre-clinical stage. These products target inflammatory and autoimmune conditions, reflecting the company's focus on specialty therapeutics.